Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05QIS
|
|||
| Former ID |
DIB016769
|
|||
| Drug Name |
VX-944
|
|||
| Synonyms |
AVN-944; AVN944; 297730-17-7; AVN 944; UNII-I3NPL1V48Q; I3NPL1V48Q; 501345-02-4; VX 944; SCHEMBL19784823; CHEMBL3349001; DTXSID80183921; EX-A778; AOB5557; ZINC3963015; AKOS027340045; CS-3427; NCGC00345803-01; NCGC00345803-05; HY-13560; AS-16899; SC-82478; (R)-1-cyanobutan-2-yl ((S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)phenyl)ethyl)carbamate; Carbamic acid, ((1S)-1-(3-((((3-methoxy-4-(5- oxazolyl)phenyl)amino)carbonyl)amino)phenyl)ethyl)-, (1R)-1-(cyanomethyl)propyl ester; (2R)-1-cyanobutan-2-yl N-[(1S)-1-[3-({[3-metho
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Company |
Avalon Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H27N5O5
|
|||
| Canonical SMILES |
CCC(CC#N)OC(=O)NC(C)C1=CC(=CC=C1)NC(=O)NC2=CC(=C(C=C2)C3=CN=CO3)OC
|
|||
| InChI |
1S/C25H27N5O5/c1-4-20(10-11-26)35-25(32)28-16(2)17-6-5-7-18(12-17)29-24(31)30-19-8-9-21(22(13-19)33-3)23-14-27-15-34-23/h5-9,12-16,20H,4,10H2,1-3H3,(H,28,32)(H2,29,30,31)/t16-,20+/m0/s1
|
|||
| InChIKey |
GYCPCOJTCINIFZ-OXJNMPFZSA-N
|
|||
| CAS Number |
CAS 297730-17-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Inosine-5'-monophosphate dehydrogenase (IMPDH) | Target Info | Inhibitor | [2] |
| Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Purine metabolism | |||
| Drug metabolism - other enzymes | ||||
| Metabolic pathways | ||||
| Pathwhiz Pathway | Purine Metabolism | |||
| Reactome | Purine ribonucleoside monophosphate biosynthesis | |||
| WikiPathways | Nucleotide Metabolism | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00493441) AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 1;24(38):5888-96. | |||
| REF 3 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitors: a patent and scientific literature review (2002-2016).Expert Opin Ther Pat. 2017 Jun;27(6):677-690. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.